# Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients

> **NCT00351715** · PHASE2 · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 5 (actual)

## Conditions studied

- Cancer
- Pain

## Interventions

- **DRUG:** Sublingual Methadone

## Key facts

- **NCT ID:** NCT00351715
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study stopped due to low accrual
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00351715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00351715, "Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00351715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*